schliessen

Filtern

 

Bibliotheken

Kidney cancer: Progress and controversies in neoadjuvant therapy

Use of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet... Full description

Journal Title: Nature Reviews Urology 2014, Vol.11(5), p.254
Main Author: Edwin M. Posadas
Other Authors: Robert A. Figlin
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 1759-4812 ; E-ISSN: 1759-4820 ; DOI: 10.1038/nrurol.2014.89
Link: http://dx.doi.org/10.1038/nrurol.2014.89
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: nature_a10.1038/nrurol.2014.89
title: Kidney cancer: Progress and controversies in neoadjuvant therapy
format: Article
creator:
  • Edwin M. Posadas
  • Robert A. Figlin
subjects:
  • Neoadjuvant Therapy – Usage
  • Neoadjuvant Therapy – Forecasts and Trends
  • Neoadjuvant Therapy – Patient Outcomes
  • Kidney Cancer – Care and Treatment
  • Kidney Cancer – Forecasts and Trends
ispartof: Nature Reviews Urology, 2014, Vol.11(5), p.254
description: Use of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet been demonstrated. Nat. Rev. Urol. 11, 254-256 (2014); published online 22 April 2014; doi:10.1038/nrurol.2014.89
language:
source:
identifier: ISSN: 1759-4812 ; E-ISSN: 1759-4820 ; DOI: 10.1038/nrurol.2014.89
fulltext: fulltext
issn:
  • 1759-4812
  • 17594812
  • 1759-4820
  • 17594820
url: Link


@attributes
ID538068941
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1038/nrurol.2014.89
sourceidnature_a
recordidTN_nature_a10.1038/nrurol.2014.89
sourcesystemPC
pqid1524818065
galeid368380412
display
typearticle
titleKidney cancer: Progress and controversies in neoadjuvant therapy
creatorEdwin M. Posadas ; Robert A. Figlin
ispartofNature Reviews Urology, 2014, Vol.11(5), p.254
identifier
source
subjectNeoadjuvant Therapy – Usage ; Neoadjuvant Therapy – Forecasts and Trends ; Neoadjuvant Therapy – Patient Outcomes ; Kidney Cancer – Care and Treatment ; Kidney Cancer – Forecasts and Trends;
descriptionUse of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet been demonstrated. Nat. Rev. Urol. 11, 254-256 (2014); published online 22 April 2014; doi:10.1038/nrurol.2014.89
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://dx.doi.org/10.1038/nrurol.2014.89$$EView_this_record_in_Nature
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Edwin M. Posadas
1Robert A. Figlin
titleKidney cancer: Progress and controversies in neoadjuvant therapy
general
0Nature Publishing Group
110.1038/nrurol.2014.89
2nature.com (Nature Publishing Group)
sourceidnature_a
recordidnature_a10.1038/nrurol.2014.89
issn
01759-4812
117594812
21759-4820
317594820
rsrctypearticle
creationdate2014
searchscopenature_a
scopenature_a
lsr30VSR-Enriched:[galeid, pages, pqid, eissn, subject, description]
sort
titleKidney cancer: Progress and controversies in neoadjuvant therapy
authorEdwin M. Posadas ; Robert A. Figlin
creationdate20140422
facets
frbrgroupid9185677665323206992
frbrtype5
creationdate2014
collectionnature.com (Nature Publishing Group)
prefilterarticles
rsrctypearticles
creatorcontrib
0Edwin M. Posadas
1Robert A. Figlin
jtitleNature Reviews Urology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Edwin M. Posadas
1Robert A. Figlin
atitleKidney cancer: Progress and controversies in neoadjuvant therapy
jtitleNature Reviews Urology
risdate20140422
volume11
issue5
spage254
issn1759-4812
genrearticle
ristypeJOUR
pubNature Publishing Group
doi10.1038/nrurol.2014.89
pages254-5
eissn17594820
date2014-04-22